Abstract:The Clinical Practice Manual for Hepatocellular Carcinoma was published based on evidence confirmed by the Evidence-based Clinical Practice Guidelines for Hepatocellular Carcinoma along with consensus opinion among a Japan Society of Hepatology (JSH) expert panel on hepatocellular carcinoma (HCC). Since the JSH Clinical Practice Guidelines are based on original articles with extremely high levels of evidence, expert opinions on HCC management in clinical practice or consensus on newly developed treatments are not included. However, the practice manual incorporates the literature based on clinical data, expert opinion, and real-world clinical practice currently conducted in Japan to facilitate its use by clinicians. Alongside each revision of the JSH Guidelines, we issued an update to the manual, with the first edition of the manual published in 2007, the second edition in 2010, the third edition in 2015, and the fourth edition in 2020, which includes the 2017 edition of the JSH Guideline. This article is an excerpt from the fourth edition of the HCC Clinical Practice Manual focusing on pathology, diagnosis, and treatment of HCC. It is designed as a practical manual different from the latest version of the JSH Clinical Practice Guidelines. This practice manual was written by an expert panel from the JSH, with emphasis on the consensus statements and recommendations for the management of HCC proposed by the JSH expert panel. In this article, we included newly developed clinical practices that are relatively common among Japanese experts in this field, although all of their statements are not associated with a high level of evidence, but these practices are likely to be incorporated into guidelines in the future. To write this article, coauthors from different institutions drafted the content and then critically reviewed each other's work. The revised content was then critically reviewed by the Board of Directors and the Planning and Public Relations Committee of JSH before publication to confirm the consensus statements and recommendations. The consensus statements and recommendations presented in this report represent measures actually being conducted at the highest-level HCC treatment centers in Japan. We hope this article provides insight into the actual situation of HCC practice in Japan, thereby affecting the global practice pattern in the management of HCC.

Asia–Pacific clinical practice guidelines on the management of hepatocellular carcinoma: a 2017 update

A concise review of updated guidelines regarding the management of hepatocellular carcinoma around the world: 2010-2016

APASL Clinical Practice Guidelines on Systemic Therapy for Hepatocellular Carcinoma-2024

Asian Consensus Workshop Report: Expert Consensus Guideline for the Management of Intermediate and Advanced Hepatocellular Carcinoma in Asia.

Pan-Asian Adapted ESMO Clinical Practice Guidelines for the Management of Patients with Intermediate and Advanced/relapsed Hepatocellular Carcinoma: a TOS-ESMO Initiative Endorsed by CSCO, ISMPO, JSMO, KSMO, MOS and SSO

Clinical Practice Guidelines For the Management of Hepatocellular Carcinoma: A Systematic Review

Summary of key guidelines for locoregional treatment of HCC in Asia, Europe, South and North America

Management consensus guideline for hepatocellular carcinoma: 2020 update on surveillance, diagnosis, and systemic treatment by the Taiwan Liver Cancer Association and the Gastroenterological Society of Taiwan

Management of Hepatocellular Carcinoma in Japan: JSH Consensus Statements and Recommendations 2021 Update

Asian-Pacific clinical practice guidelines on the management of hepatitis B: a 2015 update

2022 KLCA-NCC Korea Practice Guidelines for the Management of Hepatocellular Carcinoma

Guidelines for the Diagnosis and Treatment of Hepatocellular Carcinoma (2019 Edition).

A Changing Paradigm for the Treatment of Intermediate-Stage Hepatocellular Carcinoma: Asia-Pacific Primary Liver Cancer Expert Consensus Statements

2018 Korean Liver Cancer Association–National Cancer Center Korea Practice Guidelines for the Management of Hepatocellular Carcinoma

A review of 2022 Chinese clinical guidelines on the management of hepatocellular carcinoma: updates and insights

Differences in Presentation and Management Patterns in Patients with Hepatocellular Carcinoma (HCC): Data from HCC Registry in Asia.

Clinical practice guidelines and real-life practice in hepatocellular carcinoma: A Japanese perspective

Clinical guidelines for early hepatocellular carcinoma treatment options: a systematic review and bibliometric analysis

Critical Appraisal of Chinese 2017 Guideline on the Management of Hepatocellular Carcinoma.

Management Consensus Guidelines for Hepatocellular Carcinoma: 2023 Update on Surveillance, Diagnosis, Systemic Treatment, and Posttreatment Monitoring by the Taiwan Liver Cancer Association and the Gastroenterological Society of Taiwan